<DOC>
	<DOC>NCT00205283</DOC>
	<brief_summary>The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of HIV-infected patients who have achieved virologic success while receiving a nelfinavir containing highly active antiretroviral therapy (HAART) regimen.</brief_summary>
	<brief_title>Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Antiretroviral naive or currently taking a nelfinavir containing HAART regimen where nelfinavir is the first protease inhibitor Patients willing to comply with the protocol Age greater than or equal to 18 years Virologically successful if already on an established regimen Prior use of a protease inhibitor exclusive of nelfinavir Required use or concomitant use of drugs that may interact with or are contraindicated with nelfinavir Use of immunomodulators or vaccines for HIV disease Intercurrent illness at the time of enrollment that, in the clinician's judgement, could influence the HIV RNA concentration Baseline ALT levels greater than five times the upper limit of normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV</keyword>
</DOC>